1 citations
,
June 2025 in “Journal of Patient Experience” Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
3 citations
,
August 2024 in “Frontiers in Endocrinology” Thyroid issues can cause alopecia areata.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
1 citations
,
June 2025 in “The Journal of Dermatology” Alopecia areata significantly affects mental health and quality of life, with many feeling stigma and few receiving adequate treatment.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
July 2025 in “Preprints.org” Specific miRNA profiles can help diagnose and treat alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Impaired autophagy may contribute to alopecia areata.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
September 2025 in “Frontiers in Immunology” Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.
8 citations
,
June 2023 in “British Journal of Dermatology” The SAAD-41 scale effectively measures the psychosocial impact of alopecia areata.
14 citations
,
July 2021 in “Bioscience Reports” Activating Tgr5 may help treat hair loss and bone loss.
4 citations
,
August 2024 in “Skin Research and Technology” The study was retracted.
Acupuncture may help with hair regrowth in alopecia areata, but more research is needed.
November 2025 in “Skin Health and Disease” Addressing alexithymia can improve anxiety and depression in alopecia areata patients.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
January 2025 in “Dermatologic Therapy” Minoxidil with betamethasone is the most effective for hair regrowth in alopecia areata.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
2 citations
,
March 2025 in “Quantitative Imaging in Medicine and Surgery” Altered hypothalamic activity may contribute to stress in alopecia areata patients.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
August 2023 in “Skin Research and Technology” Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
1 citations
,
May 2025 in “Australasian Journal of Dermatology” Caregivers of teens with alopecia areata face significant mental and work-related challenges.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.